This study revealed the seroprevalences of IgM antibodies of recovered patients with COVID-19 at long-term follow-up (follow-up time ≥ 6 months) was 27%, although there was considerable heterogeneity between included studies, the results were statistically credible and reliable based on funnel plots and sensitivity analysis. The gene discussed is CD40LG; the disease is COVID-19.